Mabic 20 mg (Tablet)

Unit Price: ৳ 80.00 (3 x 10: ৳ 2,400.00)

Strip Price: ৳ 800.00

Medicine Details

Treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
Treatment of chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including Imatinib
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy
Treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase
Treatment of newly diagnosed Ph+ ALL in combination with chemotherapy

Inhibition of BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ kinases
Ability to bind to multiple conformations of the ABL kinase
Activity in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease
Inhibition of the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL
Predicted absorption pattern with maximum plasma concentrations observed between 0.5 to 6 hours following oral administration
Apparent volume of distribution of 2505 with 96% binding to human plasma proteins
Metabolism primarily by CYP3A4 with active metabolite representing approximately 5% of the AUC of Dasatinib
Excretion primarily via the feces, with 4% of administered radioactivity recovered in the urine

Recommended starting dosage of 100 mg for chronic phase CML in adults, and 140 mg for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults
Dosage based on body weight for pediatric patients, with recommended doses of 40 mg to 100 mg
Administration with or without food, either in the morning or in the evening
Tablets should not be crushed, cut, or chewed; they should be swallowed whole

Coadministration with strong CYP3A inhibitors may increase Mabic concentrations
Coadministration with strong CYP3A4 inducers may decrease Mabic concentrations
Coadministration with gastric acid reducing agents may decrease the concentrations of Mabic

Contraindicated in patients with known hypersensitivity to Dasatinib or to any component of the formulation

Potential to cause fetal harm when administered to a pregnant woman
Females of reproductive potential advised to avoid pregnancy during treatment with Dasatinib
Breastfeeding not recommended during treatment with Dasatinib and for 2 weeks after the final dose

Limited experience with overdose, severe myelosuppression and bleeding reported in isolated cases